| Estimation of benefits, burden, and harms of colorectal cancer screening strategies: modeling study for the US Preventive Services Task Force AB Knudsen, AG Zauber, CM Rutter, SK Naber, VP Doria-Rose, ... Jama 315 (23), 2595-2609, 2016 | 514 | 2016 |
| Comparing SurePath, ThinPrep, and conventional cytology as primary test method: SurePath is associated with increased CIN II+ detection rates K Rozemeijer, C Penning, AG Siebers, SK Naber, SM Matthijsse, ... Cancer Causes & Control 27, 15-25, 2016 | 77 | 2016 |
| Offering self-sampling to non-attendees of organized primary HPV screening: when do harms outweigh the benefits? K Rozemeijer, IMCM de Kok, SK Naber, FJ van Kemenade, C Penning, ... Cancer Epidemiology, Biomarkers & Prevention 24 (5), 773-782, 2015 | 63 | 2015 |
| Cost-effectiveness of a multitarget stool DNA test for colorectal cancer screening of Medicare beneficiaries SK Naber, AB Knudsen, AG Zauber, CM Rutter, SE Fischer, CJ Pabiniak, ... PloS one 14 (9), e0220234, 2019 | 58 | 2019 |
| Cost-effectiveness of risk-stratified colorectal cancer screening based on polygenic risk: current status and future potential SK Naber, S Kundu, KM Kuntz, WD Dotson, MS Williams, AG Zauber, ... JNCI cancer spectrum 4 (1), pkz086, 2020 | 51 | 2020 |
| Allocating CO2 emission to customers on a distribution route SK Naber, DA de Ree, R Spliet, W van den Heuvel Omega 54, 191-199, 2015 | 46 | 2015 |
| Cervical cancer screening in partly HPV vaccinated cohorts–A cost-effectiveness analysis SK Naber, SM Matthijsse, K Rozemeijer, C Penning, IMCM de Kok, ... PloS one 11 (1), e0145548, 2016 | 40 | 2016 |
| Cost-effectiveness of personalized screening for colorectal cancer based on polygenic risk and family history DR Cenin, SK Naber, AC de Weerdt, MA Jenkins, DB Preen, HC Ee, ... Cancer epidemiology, biomarkers & prevention 29 (1), 10-21, 2020 | 36 | 2020 |
| Cost‐effectiveness of HPV‐based cervical screening based on first year results in the Netherlands: a modelling study EEL Jansen, SK Naber, CA Aitken, HJ de Koning, M van Ballegooijen, ... BJOG: An International Journal of Obstetrics & Gynaecology 128 (3), 573-582, 2021 | 34 | 2021 |
| Cost effectiveness of age-specific screening intervals for people with family histories of colorectal cancer SK Naber, KM Kuntz, NB Henrikson, MS Williams, N Calonge, ... Gastroenterology 154 (1), 105-116. e20, 2018 | 32 | 2018 |
| Cervical cancer incidence after normal cytological sample in routine screening using SurePath, ThinPrep, and conventional cytology: population based study K Rozemeijer, SK Naber, C Penning, LIH Overbeek, CWN Looman, ... bmj 356, 2017 | 32 | 2017 |
| Beware of kinked frontiers: a systematic review of the choice of comparator strategies in cost-effectiveness analyses of human papillomavirus testing in cervical screening JF O’Mahony, SK Naber, C Normand, L Sharp, JJ O’Leary, IMCM de Kok Value in Health 18 (8), 1138-1151, 2015 | 28 | 2015 |
| Calculation of stop ages for colorectal cancer screening based on comorbidities and screening history DR Cenin, J Tinmouth, SK Naber, C Dubé, BR McCurdy, L Paszat, ... Clinical Gastroenterology and Hepatology 19 (3), 547-555, 2021 | 25 | 2021 |
| Optimizing management of patients with Barrett’s esophagus and low-grade or no dysplasia based on comparative modeling AH Omidvari, A Ali, WD Hazelton, S Kroep, M Lee, SK Naber, BN Lauren, ... Clinical Gastroenterology and Hepatology 18 (9), 1961-1969, 2020 | 19 | 2020 |
| The optimal age to stop endoscopic surveillance of patients with Barrett’s esophagus based on sex and comorbidity: a comparative cost-effectiveness analysis AH Omidvari, WD Hazelton, BN Lauren, SK Naber, M Lee, A Ali, C Seguin, ... Gastroenterology 161 (2), 487-494. e4, 2021 | 18 | 2021 |
| Reducing unnecessary referrals for colposcopy in hrHPV-positive women within the Dutch cervical cancer screening programme: A modelling study S Kaljouw, EEL Jansen, CA Aitken, LM Harrijvan, SK Naber, ... Gynecologic Oncology 160 (3), 713-720, 2021 | 18 | 2021 |
| Modeling in colorectal cancer screening: assessing external and predictive validity of miscan-colon microsimulation model using norccap trial results M Buskermolen, A Gini, SK Naber, E Toes-Zoutendijk, HJ de Koning, ... Medical Decision Making 38 (8), 917-929, 2018 | 15 | 2018 |
| Costs and outcomes of Lynch syndrome screening in the Australian colorectal cancer population DR Cenin, SK Naber, I Lansdorp‐Vogelaar, MA Jenkins, DD Buchanan, ... Journal of Gastroenterology and Hepatology 33 (10), 1737-1744, 2018 | 15 | 2018 |
| The potential harms of primary human papillomavirus screening in over-screened women: a microsimulation study SK Naber, IMCM de Kok, SM Matthijsse, M van Ballegooijen Cancer Causes & Control 27, 569-581, 2016 | 15 | 2016 |
| Cost-effectiveness of active identification and subsequent colonoscopy surveillance of Lynch syndrome cases EFP Peterse, SK Naber, C Daly, A Pollett, LF Paszat, MCW Spaander, ... Clinical Gastroenterology and Hepatology 18 (12), 2760-2767. e12, 2020 | 13 | 2020 |
